Novartis Honors Those Impacted by Soft Tissue Sarcoma (STS) During Sarcoma Awareness Month
Jul 20, 2016
July is Sarcoma Awareness Month, and Novartis is committed to raising awareness of soft tissue sarcoma (STS) around the world. We are honored to join thousands of patients, caregivers, advocates, healthcare teams and researchers to break the silence around this rare cancer. Education is key in building awareness of STS, and we are dedicated to providing resources that can help people better understand the disease and support the needs of those who live with it.
Soft tissue sarcoma can develop from connective tissues like:
As many as five in 100,000 people worldwide are diagnosed with a soft tissue sarcoma every year.
1 in 2 diagnosed with STS have or are expected to progress to advanced disease
Sign and symptoms of STS are subtle or non-specific, making it difficult to detect the disease in early stages
Receiving an STS diagnosis can be overwhelming, and it is important that patients feel empowered to talk with their multidisciplinary healthcare team about specific concerns and work collaboratively to determine an individual disease management plan.
Know you are not alone, and others want to help. It can make a big difference to seek emotional support from:
Advocacy Groups (e.g., Sarcoma Alliance, Sarcoma Foundation of America, Sarcoma UK, Sarah-Grace Sarcoma Foundation, Sarcoma Cancer Foundation of Canada)
The patient community inspires us to remain dedicated to the research, development and delivery of innovative treatments to help improve care for those living with and managing STS. If you’d like to learn more, our website has additional information on soft tissue sarcoma.